Presentation is loading. Please wait.

Presentation is loading. Please wait.

Anti-IgE treatment of eosinophil-associated gastrointestinal disorders

Published byAugustine Marsh Modified over 6 years ago

Similar presentations

Presentation on theme: "Anti-IgE treatment of eosinophil-associated gastrointestinal disorders"— Presentation transcript:

1 Anti-IgE treatment of eosinophil-associated gastrointestinal disorders
Shabnam Foroughi, MD, Barbara Foster, MS, NaYoung Kim, MD, Leigh B. Bernardino, RN, Linda M. Scott, CRNP, Robert G. Hamilton, PhD, Dean D. Metcalfe, MD, Peter J. Mannon, MD, Calman Prussin, MD  Journal of Allergy and Clinical Immunology  Volume 120, Issue 3, Pages (September 2007) DOI: /j.jaci Copyright © 2007 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 Effect of omalizumab on peripheral blood eosinophil counts. Peripheral blood AECs were determined at baseline (week 0) and every 2 weeks thereafter for the duration of the study. The actual values for each time point (A), as well as the value as a percentage of the preomalizumab baseline (B), are shown. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2007 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 2 Effect of omalizumab on tissue eosinophil counts. Esophagogastroduodenoscopy was performed at baseline and again after 16 weeks of omalizumab therapy, and the median number of eosinophils per hpf in the duodenum (A), gastric antrum (B) and body (C), and esophagus (D) were determined. Data are shown as the median value for each subject. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2007 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Fig 3 Efficacy of omalizumab in blocking IgE. Changes in the levels of serum free IgE (A), basophil-associated IgE (B), FcɛRI expression by peripheral blood basophils (C), myeloid DCs (mDC; D), and pDCs (E) are shown. The above were determined at baseline and again after 16 weeks of omalizumab. Free IgE was determined at baseline and serially thereafter. ∗P < .005 for each time point relative to baseline. Fluorescence intensity was quantitated as molecules of equivalent phycoerythrin (MEPE). Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2007 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5 Fig 4 Efficacy of omalizumab in blocking basophil activation. Basophil CD63 expression after in vitro activation by anti-IgE (A) and allergen (data not shown) was measured, and the EC50 was calculated for each, respectively (B and C). D and E, Constitutive basophil CD63 expression without or with added IL-3. F, Basophil CD63 expression after N-formyl-methionine-leucine-phenylalanine activation. The results were determined at baseline and again after 16 weeks of omalizumab. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2007 American Academy of Allergy, Asthma & Immunology Terms and Conditions

6 Fig 5 Efficacy of omalizumab in blocking immediate hypersensitivity. Wheal (A) and erythema (B) after food and aeroallergen titration skin testing at baseline and after 16 weeks of omalizumab. Each result is the mean of 2 skin tests. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2007 American Academy of Allergy, Asthma & Immunology Terms and Conditions

7 Fig 6 Effect of omalizumab on EGID symptom scores. A, EGID symptom scores at baseline, midstudy (weeks 7-8), and end of study (weeks 15-16). B, EGID symptom scores were calculated as a percentage of the baseline value for each subject. ∗P < .005 for each time point relative to baseline. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2007 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Download ppt "Anti-IgE treatment of eosinophil-associated gastrointestinal disorders"

Similar presentations

Nasal challenge with allergen leads to maxillary sinus inflammation

Nasal challenge with allergen leads to maxillary sinus inflammation
Incidence of parentally reported and clinically diagnosed food hypersensitivity in the first year of life  Carina Venter, BSc, Brett Pereira, MRCP, Jane.

Incidence of parentally reported and clinically diagnosed food hypersensitivity in the first year of life  Carina Venter, BSc, Brett Pereira, MRCP, Jane.
Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy  Ravi S. Swamy, MD, Neha Reshamwala,

Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy  Ravi S. Swamy, MD, Neha Reshamwala,
Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS 

Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS 
Corinne A. Keet, MD, MS, Pamela A

Corinne A. Keet, MD, MS, Pamela A
A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,

A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,
Incidence of parentally reported and clinically diagnosed food hypersensitivity in the first year of life  Carina Venter, BSc, Brett Pereira, MRCP, Jane.

Incidence of parentally reported and clinically diagnosed food hypersensitivity in the first year of life  Carina Venter, BSc, Brett Pereira, MRCP, Jane.
Advances in food allergy in 2015

Advances in food allergy in 2015
Role of the basophil activation test in the diagnosis of local allergic rhinitis  Enrique Gómez, PhD, Paloma Campo, MD, PhD, Carmen Rondón, MD, PhD, Esther.

Role of the basophil activation test in the diagnosis of local allergic rhinitis  Enrique Gómez, PhD, Paloma Campo, MD, PhD, Carmen Rondón, MD, PhD, Esther.
Ibrutinib, a Bruton’s tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil.

Ibrutinib, a Bruton’s tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil.
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Omalizumab treatment downregulates dendritic cell FcεRI expression

Omalizumab treatment downregulates dendritic cell FcεRI expression
Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 
Is 9 more than 2 also in allergic airway inflammation?

Is 9 more than 2 also in allergic airway inflammation?
A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy  Robert A.

A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy  Robert A.
Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge  Yee Ean Ong, MBBS, Andrew Menzies-Gow,

Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge  Yee Ean Ong, MBBS, Andrew Menzies-Gow,
Mass cytometry profiling the response of basophils and the complete peripheral blood compartment to peanut  Leticia Tordesillas, PhD, Adeeb H. Rahman,

Mass cytometry profiling the response of basophils and the complete peripheral blood compartment to peanut  Leticia Tordesillas, PhD, Adeeb H. Rahman,
Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils  Henry Lin, MD, Kevin M Boesel, MD, Daniel T Griffith, MD, Calman Prussin,

Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils  Henry Lin, MD, Kevin M Boesel, MD, Daniel T Griffith, MD, Calman Prussin,
Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J
Katherine N. Cahill, MD, Jillian C. Bensko, Joshua A

Katherine N. Cahill, MD, Jillian C. Bensko, Joshua A

Similar presentations

Ads by Google